VRIO Analysis of Licensing of APOEP1 B Peptide Technology

Posted by Zachary Edwards on Mar-22-2018

The VRIO Analysis of Licensing of APOEP1 B Peptide Technology will look at each of its internal resources one by one to assess whether these provide sustained competitive advantage. The Licensing of APOEP1 B Peptide Technology VRIO Analysis also mentions at each stage whether these resources could be improved to provide a greater competitive advantage. Lastly, the resources analysed are summarised as to whether they offer sustained competitive advantage, has an unused competitive advantage, temporary competitive advantage, competitive parity or competitive disadvantage.

Valuable

• The Licensing of APOEP1 B Peptide Technology VRIO Analysis shows that the financial resources of Licensing of APOEP1 B Peptide Technology are highly valuable as these help in investing into external opportunities that arise. These also help Licensing of APOEP1 B Peptide Technology in combating external threats.
• According to the VRIO Analysis of Licensing of APOEP1 B Peptide Technology, its local food products are a valuable resource as these are highly differentiated. This makes the perceived value for these by customers high. These are also valued more than the competition by customers due to the differentiation in these products.
• The Licensing of APOEP1 B Peptide Technology VRIO Analysis shows that Licensing of APOEP1 B Peptide Technology's employees are a valuable resource to the firm. A significant portion of the workforce is highly trained, and this leads to more productive output for the organisation. The employees are also loyal, and retention levels for the organisation are high. All of this translates into greater value for the end consumers of Licensing of APOEP1 B Peptide Technology's products.
• According to the VRIO Analysis of Licensing of APOEP1 B Peptide Technology, its patents are a valuable resource as these allow the firm to sell its products without competitive interference. This results in greater revenue for Licensing of APOEP1 B Peptide Technology. These patents also provide Licensing of APOEP1 B Peptide Technology with licensing revenue when it licenses these patents out to other manufacturers.
• The Licensing of APOEP1 B Peptide Technology VRIO Analysis shows that Licensing of APOEP1 B Peptide Technology’s distribution network is a valuable resource. This helps it in reaching out to more and more customers. This ensures greater revenues for Licensing of APOEP1 B Peptide Technology. It also ensures that promotion activities translate into sales as the products are easily available.
• According to the VRIO Analysis of Licensing of APOEP1 B Peptide Technology, its cost structure is not a valuable resource. This is because the methods of production lead to greater costs than that of competition, which affects the overall profits of the firm. Therefore, its cost structure is a competitive disadvantage that needs to be worked on.
• The Licensing of APOEP1 B Peptide Technology VRIO Analysis shows that the research and development at Licensing of APOEP1 B Peptide Technology is not a valuable resource. This is because research and development are costing more than the benefits it provides in the form of innovation. There have been very few innovative features and breakthrough products in the past few years. Therefore, research and development are a competitive disadvantage for Licensing of APOEP1 B Peptide Technology. It is recommended that the research and development teams are improved, and costs are cut for these.

Rare

• The financial resources of Licensing of APOEP1 B Peptide Technology are found to be rare according to the VRIO Analysis of Licensing of APOEP1 B Peptide Technology. Strong financial resources are only possessed by a few companies in the industry.
• The local food products are found to be not rare as identified by Licensing of APOEP1 B Peptide Technology VRIO Analysis. These are easily provided in the market by other competitors. This means that competitors can use these resources in the same way as Licensing of APOEP1 B Peptide Technology and inhibit competitive advantage. This means that the local food products result in competitive parity for Licensing of APOEP1 B Peptide Technology. As this resource is valuable, Licensing of APOEP1 B Peptide Technology can still make use of this resource.
• The employees of Licensing of APOEP1 B Peptide Technology are a rare resource as identified by the VRIO Analysis of Licensing of APOEP1 B Peptide Technology. These employees are highly trained and skilled, which is not the case with employees in other firms. The better compensation and work environment ensure that these employees do not leave for other firms.
• The patents of Licensing of APOEP1 B Peptide Technology are a rare resource as identified by the Licensing of APOEP1 B Peptide Technology VRIO Analysis. These patents are not easily available and are not possessed by competitors. This allows Licensing of APOEP1 B Peptide Technology to use them without interference from the competition.
• The distribution network of Licensing of APOEP1 B Peptide Technology is a rare resource as identified by the VRIO Analysis of Licensing of APOEP1 B Peptide Technology. This is because competitors would require a lot of investment and time to come up with a better distribution network than that of Licensing of APOEP1 B Peptide Technology. These are also possessed by very few firms in the industry.

Imitable

• The financial resources of Licensing of APOEP1 B Peptide Technology are costly to imitate as identified by the Licensing of APOEP1 B Peptide Technology VRIO Analysis. These resources have been acquired by the company through prolonged profits over the years. New entrants and competitors would require similar profits for a long period of time to accumulate these amounts of financial resources.
• The local food products are not that costly to imitate as identified by the VRIO Analysis of Licensing of APOEP1 B Peptide Technology. These can be acquired by competitors as well if they invest a significant amount in research and development. These also do not require years long experience. Therefore, the local food products by Licensing of APOEP1 B Peptide Technology provide it with a temporary competitive advantage that competitors can too acquire in the long run.
• The employees of Licensing of APOEP1 B Peptide Technology are also not costly to imitate as identified by the Licensing of APOEP1 B Peptide Technology VRIO Analysis. This is because other firms can also train their employees to improve their skills. These companies can also hire employees from Licensing of APOEP1 B Peptide Technology by offering better compensation packages, work environment, benefits, growth opportunities etc. This makes the employees of Licensing of APOEP1 B Peptide Technology a resource that provides a temporary competitive advantage. Competition can acquire these in the future.
• The patents of Licensing of APOEP1 B Peptide Technology are very difficult to imitate as identified by the VRIO Analysis of Licensing of APOEP1 B Peptide Technology. This is because it is not legally allowed to imitate a patented product. Similar resources to be developed and getting a patent for them is also a costly process.
• The distribution network of Licensing of APOEP1 B Peptide Technology is also very costly to imitate by competition as identified by the Licensing of APOEP1 B Peptide Technology VRIO Analysis. This has been developed over the years gradually by Licensing of APOEP1 B Peptide Technology. Competitors would have to invest a significant amount if they are to imitate a similar distribution system.

Organisation

• The financial resources of Licensing of APOEP1 B Peptide Technology are organised to capture value as identified by the VRIO Analysis of Licensing of APOEP1 B Peptide Technology. These resources are used strategically to invest in the right places; making use of opportunities and combatting threats. Therefore, these resources prove to be a source of sustained competitive advantage for Licensing of APOEP1 B Peptide Technology.
• The Patents of Licensing of APOEP1 B Peptide Technology are not well organised as identified by the Licensing of APOEP1 B Peptide Technology VRIO Analysis. This means that the organisation is not using these patents to their full potential. An unused competitive advantage exists that can be changed into a sustainable competitive advantage if Licensing of APOEP1 B Peptide Technology starts selling patented products before the patents expire.
• The distribution network of Licensing of APOEP1 B Peptide Technology is organised as identified by the VRIO Analysis of Licensing of APOEP1 B Peptide Technology. Licensing of APOEP1 B Peptide Technology uses this network to reach out to its customers by ensuring that products are available on all of its outlets. Therefore, these resources prove to be a source of sustained competitive advantage for Licensing of APOEP1 B Peptide Technology.

From the VRIO Analysis of Licensing of APOEP1 B Peptide Technology, it was identified that the financial resources and distribution network provide a sustained competitive advantage. The patents are a source of unused competitive advantage. There exists a temporary competitive advantage for employees. There exists a competitive parity for local food products. Lastly, the cost structure of Licensing of APOEP1 B Peptide Technology is a competitive disadvantage. Research and Development is also a competitive disadvantage.